Advertisement
U.S. markets closed

Biodexa Pharmaceuticals Plc (BDRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3600+0.0900 (+7.09%)
At close: 04:00PM EST
1.3300 -0.03 (-2.21%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close1.2700
Open1.3000
Bid1.3100 x 1100
Ask1.3700 x 900
Day's Range1.2900 - 1.4300
52 Week Range1.2100 - 166.4000
Volume544,222
Avg. Volume606,473
Market Cap3.563M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-876.0200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BDRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Biodexa Pharmaceuticals plc
    Analyst Report: J.B. Hunt Transport Services, Inc.J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales in 2023); dedicated trucking services that provide customer-specific fleet needs (28%); for-hire truckload (6%); heavy goods final-mile delivery (7%), and asset-light truck brokerage (11%).
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • ACCESSWIRE

    Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

    Orally dosed small molecule candidate is designed to reduce/eliminate need for injectable insulin Topline data from Phase 2a program expected by year-end Safety profile established in more than 700 patients CARDIFF, UK / ACCESSWIRE / March 1, 2024 ...

  • GlobeNewswire

    Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

    Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall Survival of 16.5 Months vs 10.0 months in Comparable Cohort CARDIFF, United Kingdom, February 23, 2024 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs i

  • GlobeNewswire

    Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

    Biodexa Pharmaceuticals PLC Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients CARDIFF, United Kingdom, February 8, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare/orphan brain cancers, today provided survival updates from its